Blog · 2026-10-28 · Ashutosh Agarwal

An Agent Swarm on Hims & Hers

A Matterfact agent swarm spent seven weeks researching Hims & Hers ahead of its 9 November results. It puts fair value below the share price, and still sees no trade worth taking. Here is what it found, and why.

Hims & Hers Health (NYSE: HIMS). Consumer telehealth, reporting Q3 results on 9 November.

7 weeks of research, 3 Sep to 25 Oct; $22.86 vs $27.71 fair value vs share price; No trade entry levels set.

Hims & Hers reports its third-quarter results on 9 November. A Matterfact agent swarm has spent seven weeks researching the company. It puts fair value at $22.86 a share, about 17% below the $27.71 the stock closed at on 23 October.

It still won't short the stock.

The conclusion matters less than how the swarm reached it. Hims' adjusted earnings and its cash flow point in different directions, and its results days bring large moves. The swarm took the reported numbers apart note by note, corrected its own model in both directions, worked out what the options market already expects, and wrote down in advance how each outcome of the results will be graded. This article sets out what it concluded, the evidence behind the view, and what it suggests for investment teams. The swarm's full investment memo is below.

kind: word
title: Hims & Hers investment memo
meta: Written by the agent swarm · as of 25 Sep 2026 · Word, 612 KB
href: /samples/hims-hers-ic-memo-2026-09-25.docx

TL;DR

• The swarm agrees with the Street on demand and disagrees on profit. Its 2027 revenue forecast is above consensus; its 2027 EBITDA forecast is 18% below.
• Adjusted EBITDA overstates what the business earns in cash. Q2's $60.3M of adjusted EBITDA was −$4.9M on a cash basis, and part of the beat may have come from releasing prepaid revenue.
• The margin everyone debates is the smallest lever on value. Customer acquisition cost and churn in the core business matter about four times more.
• Being right on the downside would earn nothing. The options market already prices almost exactly the fall the swarm expects, so it has no trade, with entry levels set.
• The view is testable. 53 dated predictions are graded within a day of the 9 November results.

heading: What we cover
Why Hims is hard to value :: hims-is-a-growth-story-whose-profit-and-cash-tell-a-different-one
Where it differs from the Street :: the-swarm-agrees-with-the-street-on-demand-and-disagrees-on-profit
Adjusted earnings vs cash :: adjusted-ebitda-overstates-what-the-business-earns-in-cash
Earnings quality in the fine print :: the-fine-print-points-to-weaker-earnings-quality
Corrections in both directions :: the-swarm-corrected-its-own-model-in-both-directions
What moves the value :: acquisition-cost-and-churn-move-the-value-not-the-margin-debate
What the market already expects :: the-market-has-already-priced-the-downside
Regulation :: regulatory-risk-is-real-but-sits-mostly-outside-the-guidance
Why it won't short the stock :: a-stock-can-be-overvalued-and-still-not-be-a-good-short
The scoreboard :: every-outcome-of-the-9-november-results-is-scored-in-advance
Questions for management and experts :: each-question-is-built-to-settle-an-open-debate
What this means for investment teams
The investment memo :: read-the-swarms-investment-memo

Hims is a growth story whose profit and cash tell a different one

On the surface, Hims is a growth story: revenue up 38% last quarter, more than 2.9 million subscribers, and a 2030 target of $6.5B of revenue and $1.3B of EBITDA.

Underneath, almost everything is changing at once:

• Weight loss changed product. Hims moved from compounded GLP-1 weight-loss drugs (pharmacy-made versions it sold at high margins) to branded drugs from Novo Nordisk and Eli Lilly. It resells those at the manufacturer's own self-pay price and books the full sale as revenue.
• The company bought growth. It acquired Eucalyptus, an Australian telehealth business, in June. International rose to 17% of revenue.
• Regulators are active. There is an FTC lawsuit (joined by Utah and Los Angeles County), an SEC inquiry, a securities class action and shifting FDA rules on compounding.
• Adjusted earnings and cash have diverged. The figures the market watches and the cash the business generates tell different stories.
• Results days bring large moves. The options market prices a 12.5% move in either direction.

So the question is not whether Hims is growing. It is whether that growth is turning into profit and cash, and what the market already expects. Answering it takes filings, alternative data, options pricing, court dockets and a valuation model, all checked against each other.

What is an agent swarm?. A team of autonomous AI agents that work toward one research goal the way an investment team would: building the valuation, reading the filings, working through the credit and testing the thesis. It runs continuously and keeps score of its own predictions.

To value Hims, the swarm assembled the evidence a sector specialist would want:

columns: 2
The filing notes :: Deferred revenue, receivables and the receivables-sale facility, the Eucalyptus acquisition note, and the bridge from net loss to adjusted EBITDA. :: evidence
11 quarters of guidance :: Guidance against actual results for every quarter since late 2023, rebuilt from the earnings releases. :: clock
Street margin estimates :: Seven quarters of consensus gross margin, from a niche source most analysts never reconcile. :: target
Results-day history :: Eight quarters of next-day stock moves, rebuilt from daily prices. :: list
The options market :: Full option chains, turned into the market's implied odds for results day. :: compass
Short interest and borrow :: Short interest, the cost to borrow the stock, shares available to borrow, and insider filings. :: users
Demand and pricing :: Search interest, app downloads and web traffic, plus 22 live captures of the Hims weight-loss page and five competitors. :: lens
Court dockets :: The federal dockets for the FTC case and the securities class action. :: shield

The swarm agrees with the Street on demand and disagrees on profit

After seven weeks, the swarm's view comes down to one sentence: it agrees with the Street on demand and disagrees on profit.

The swarm is above the Street on 2027 revenue and 18% below on 2027 EBITDA. The difference is margin and cash, not demand.

Gross margin has fallen every quarter for a year, and the swarm expects another drop Hims & Hers gross margin by quarter (%), and the swarm's Q3 forecast. A Q3 margin of 61.8% or more would prove the swarm wrong; 64% is the Q2 level.

Swarm's Q3 forecast: 63.8% on 30 Jun 2026, 60.6% on 30 Sep 2026 (2 observations).

The swarm named the number that would prove it wrong. On its own cost assumptions, a Q3 gross margin of 61.8% is enough to hit the $85M EBITDA midpoint. At or above that level, its margin view is wrong.

The forecast drop of 3.2 points from Q2 is larger than the Street appears to assume, so the swarm was challenged to defend it. It did, with a bridge in which every piece traces to a filing:

• −1.96 points from a full quarter of Eucalyptus;
• −1.41 points from more branded weight loss;
• +0.17 points from the core business.

The share price tells the same story. Holding the swarm's revenue forecast, a price of $28.39 (the model's reference price) needs a 2030 EBITDA margin of about 20%, roughly $1.15B, or about 90% of management's $1.3B target. The swarm's base case has 13.6%, or $770M.

Adjusted EBITDA overstates what the business earns in cash

It threw out a popular bearish argument first

The work started with a common bear case: Hims' gross margin was "really" about 51%, and the reported 64% was flattered by non-cash add-backs. If true, that would be a 13-point quality problem. The quarterly filing (the 10-Q) said otherwise:

• Reported gross profit of $480.8M on $753.2M of revenue is 63.8%, with no add-backs.
• $0 of stock-based pay sits in cost of revenue, and no amortisation does either.
• The 51% only appears if $95.5M of operations and support costs are moved up into cost of goods.

The “51% gross margin” is a choice about where to book costs Hims & Hers Q2 FY2026, % of revenue.

The swarm dropped the argument and turned its scrutiny to the number that deserved it.

The real gap is between adjusted EBITDA and cash

Hims reported $60.3M of adjusted EBITDA for Q2, the profit measure the company and the market focus on. The swarm split the $28.8M "acquisition and transaction" add-back into two parts:

• About $12M of one-time deal fees. Fair to add back.
• About $16.8M of pay for staff of acquired businesses, tied to them staying on. It comes out of a $131.3M pool expensed over several years, so it is a recurring cost.

It then treated stock-based pay, the payroll tax on it and an earn-out revaluation as real costs:

Q2 adjusted EBITDA of $60.3M was −$4.9M in cash Hims & Hers Q2 FY2026, from reported adjusted EBITDA to cash EBITDA, $M.

• Free cash flow was −$68.2M: a $128.5M gap to the headline EBITDA in a single quarter.
• On the same basis, the $300M midpoint of full-year guidance is worth about $252M excluding acquisition pay, and about $45M in cash EBITDA.

The swarm's summary: "the ramp is real on paper and thin in cash."

The Q4 ramp is hard to square with demand

Full-year guidance implies Q4 EBITDA of about $110M. That needs a 43% incremental margin (43 cents of EBITDA on each extra dollar of revenue), with marketing held near 34% of revenue in the heaviest customer-acquisition quarter of the year. Meanwhile, US search interest in the Hims brand was down 21.7% year on year, while interest in Wegovy, the branded drug, was up 89–99%. Holding marketing flat while organic demand shrinks and revenue keeps growing is difficult, and the swarm recorded it as a weakness in the bullish case.

The fine print points to weaker earnings quality

The most valuable findings came from filing notes a typical model never touches.

Part of the Q2 beat may have been prepaid revenue

A bank research note suggested Q2 weight-loss results benefited from deferred revenue on compounded GLP-1 plans. The swarm checked it against the 10-Q:

• Deferred revenue fell from $165.1M at 31 March to $141.4M at 30 June.
• The quarter's net release was $23.7M on the balance sheet and $35.0M in the cash-flow statement, against about $12.3M a year earlier.
• The swarm estimates the excess release lifted EBITDA by $7.9–18.1M. The beat against the guidance midpoint was $15.3M.

So between half and all of the beat may have come from customer prepayments rolling off rather than new business. The swarm set a test for the Q3 10-Q to tell the two apart.

Cash flow could be flattered by selling receivables

First-half receivables jumped. The swarm traced $347.4M of the build to rebates owed by drug makers, money that passes straight through. It then found a $400M facility, signed on 1 July, that lets Hims sell those receivables for cash. That could fund the second-half cash-flow turn management has promised.

So the swarm committed in advance to judge cash flow without the facility. Its test: Q3 operating cash flow is positive as reported, but $25M or less excluding receivables sold.

Compounded revenue sits inside the "core" business

The model's "core" business was meant to be hair, skin and sexual health. The swarm found about $75M a quarter of compounded GLP-1 revenue inside it, at about 65% margin rather than the 75–85% usually assumed for core. It ran the consequence both ways:

• If those customers leave for good, value falls by up to $5.08 a share.
• If they churn at a normal rate and the rest of the core shifts toward higher margins, value rises by up to $3.66.

The net effect, about −$0.35, was too small to change the number, so it became a test for the 10-Q instead.

Weight-loss customers do not yet pay back their acquisition cost

• Growth without gross profit. Revenue per subscriber rose 21% year on year in Q2; gross profit per subscriber rose 1.4%. Of 307K net subscriber additions, about 185K came with the Eucalyptus acquisition. US revenue grew 16%, against 38% for the group.
• Monthly billing raises cancellations. Moving branded weight-loss customers from prepaid plans to monthly billing adds about 2 points a month to churn, because the subscription is tested twelve times a year instead of a few.
• The customer does not pay back. On the swarm's numbers, only about 33% of branded weight-loss customers are still subscribed after 12 months (28–42% across three methods), and each returns about 0.7x its acquisition cost over 24 months. Retention of 45% or better would make them value-creating.
• Disputes and refunds. In August, Hims was placed in a card network's dispute-monitoring program after a surge in customer disputes in July. That ended the swarm's assumption that refund and discount leakage would fade. Its test: Hims exits the program with no escalation by 31 January 2027.
• The live price check. On 23 October, the swarm re-read hims.com and five competitors' sites (22 captures). The price was still $39 for the first month, then $149, with no prepaid tier. New: a generic anti-nausea prescription and AI support are included at the same fee, an early sign that Hims may defend price with added features rather than a discount.

The swarm corrected its own model in both directions

A stricter model, honestly labelled

On 24 September, the swarm adopted a stricter valuation model and fair value fell to $24.34. It broke the drop down rather than blaming the business:

• About $710M of debt-like claims, roughly $2.50 a share, now come off equity value: deferred acquisition payments, an earn-out, a legal accrual and the acquisition-linked pay.
• Stock-based pay is treated as a cash cost.
• Gross margin was rebuilt bottom-up at 61–62% instead of 64%.
• A dilution adjustment from the old model was removed, so the same cost was not counted twice.

Its verdict: about 60% of the cut came from a stricter method, not a worse business. It also recorded the uncomfortable part. Most investors value Hims on adjusted EBITDA with a simple debt bridge, so part of the "overvalued" call rests on a convention the market may never adopt. The swarm logged that as a challenge to its own view.

International was bigger than assumed

One challenge treated international as about 5% of revenue. The filings showed 12.9% in Q1 and 17.4% in Q2, heading toward 25%. That mix alone takes the margin on the non-weight-loss business from 76.6% to 73.7%. The swarm also caught that its model assumed US margins would improve, even though the 10-Q says pressure from more frequent shipping "will continue". It held them flat.

A margin nobody discloses, estimated four ways

The model assumed Eucalyptus earns a 52% gross margin. The deal fell below the size that requires audited financials, and no amended filing exists. So the swarm triangulated:

Four estimates put Eucalyptus' gross margin near 44%, well below the 52% the model assumed Eucalyptus gross margin by method (%). The adopted estimate in navy; the original assumption in grey.

The swarm also caught the knock-on. If Eucalyptus earned less in Q2, the rest of the business must have earned more to reach the reported total, so it raised the US margin rather than cutting twice. Net effect: −$1.22 a share. Rebuilt from the 10-Q's pro-forma figures, Eucalyptus brings in about $126M a quarter, up about 108% year on year, so roughly 5 points of Hims' reported growth came from the acquisition rather than the existing business.

Weight-loss margin, built from its parts

Hims sells branded GLP-1 drugs at the manufacturer's own self-pay price, so it earns close to nothing on the drug itself. Branded weight-loss gross margin is roughly the membership fee's share of the bill plus an undisclosed rebate. The fee, $149 a month after a $39 first month, is about four times more powerful than any other part of that margin.

The swarm modelled the likely year-end pricing moves as a tree: new features at the same price, a commitment or prepaid plan, or a headline cut to $99 or less. It removed an assumed climb in margin from 22% toward 24% that held in only one branch. Fair value fell $0.74.

Then the evidence pushed the value back up

By late September, the swarm put a 63% chance on Q3 EBITDA landing at or below the guidance midpoint. Then it checked the company's record:

• In 11 quarters, Hims has never reported EBITDA below the bottom of its guidance range.
• It beat the midpoint 10 times out of 11.
• In Q2 it beat by 34% even as gross margin fell 6 points.

Rebuilt line by line, the swarm's bearish view turned out to be a pure gross-margin bet. Assuming 60.6% instead of 64% cost $30.1M against the midpoint; on marketing and every other cost line, the swarm was more optimistic than management. It blended three views equally:

Checking the company's record cut the chance of a weak quarter from 63% to 46% Chance Q3 EBITDA lands at or below the guidance midpoint, late September (%): the estimate before the check in grey, three views in blue, the adopted blend in navy.

Fair value rose $1.77. Within the hour, that upward move was challenged too. The CFO had said the second quarter's gross margin "dynamics" would persist through the second half, which describes a trend, not a 64% level. Read that way, about $0.50 of the gain disappears. The swarm logged the caveat and tied it to a test dated for the day after the results.

Every step, on the record

Fair value fell from $31.29 to $22.86 in 24 days, with one large step back up Hims & Hers: every change to the swarm's fair value, 3 to 27 September, $ per share.

Fair value fell as the swarm took the numbers apart, then held while the stock ranged Hims & Hers, $ per share: the swarm's fair value vs the daily closing share price.

HIMS share price: $27.83 on 3 Sep 2026, $27.71 on 23 Oct 2026 (36 observations).

Marked events: 24 Sep 2026, Stricter model; 15 Oct 2026, Peptide report: stock +6%.

It checked its own blind spots

• It downgraded its own favourite data. Brand search interest looked like an early warning on demand, so the swarm tested whether search had ever predicted Hims' reported revenue. It had not (correlation 0.08–0.13), so search is a directional signal only, never a number in the model.
• It noticed when it was blind. For four days in mid-September, news searches on a heavily litigated stock returned nothing. Hims' biggest regulatory moves arrive through court dockets and agency actions, which never appear as SEC filings, so the swarm went to the federal court record. In doing so, it corrected its own calendar: the FTC case conference is on 30 October, before the results, not 30 November.

It challenged its bearish view as hard as the bullish one

At least seven times, the swarm was challenged on whether it was too bearish:

It also rejected bearish ideas that did not hold up:

Acquisition cost and churn move the value, not the margin debate

Core acquisition cost and churn move fair value four times more than weight-loss margin Hims & Hers: swing in base-case fair value as each input moves, $ per share. The margin everyone debates in navy.

The debate everyone has about Hims, weight-loss gross margin, is the smallest lever on value. Acquisition cost and churn in the core hair, skin and sexual-health business are about four times bigger.

Gross margin matters for how the stock reacts on 9 November. For what the business is worth, the core's unit economics matter far more, and several of the swarm's sharpest questions for management and experts target them.

The market has already priced the downside

The swarm turned option prices into the market's implied odds for results day:

On the downside, the market and the swarm agree almost exactly, so being right about the bear case would earn nothing. On the upside, the swarm is more pessimistic. It took that seriously and added a sixth outcome to its results map: a big fundamental beat, with the stock up about 24%.

Beating guidance has not been enough

Hims beat its EBITDA guidance in 7 of its last 8 results; the stock fell after 7 Hims & Hers: the stock's move the day after each result (%). Each label shows how far EBITDA beat the midpoint of the company's own guidance.

Fitting the stock's reaction to the size of the beat across 11 results, Hims needs to beat its midpoint by about 24%, roughly $106M of Q3 EBITDA against an $85M midpoint, just for the stock to hold flat. In August it beat by 34% and still fell 4%. Rebuilding this history, the swarm also caught an error in its own records: one quarter had been logged as −8% when the stock actually rose 18.1%.

Run-ups before results have also ended badly. When Hims rose 25% or more in the 20 days before results, the stock fell an average of 7.7% on the day (4 cases, 3 down), against an average fall of 2.1% otherwise. So the swarm would bet against a pre-results rally only if it came with no news behind it.

Hims beats on EBITDA but misses on gross margin

Hims missed the Street's gross margin in 5 of its last 7 results Hims & Hers: gross margin vs Street consensus at each result, percentage points.

Hims fell short of the Street's gross margin 5 times out of 7, by 1.9 points on average across the seven, while beating its EBITDA guidance 10 times out of 11. The company delivers EBITDA by managing costs, not margin. On 9 November, gross margin is the number to watch.

Two more signals on how the results will land

• Guidance has started landing below the Street. This year, full-year guidance has come in below consensus when issued (three clear cases and one mixed); in 2024–25 it came in above or in line. The swarm puts a 55% chance on the new full-year EBITDA midpoint landing below the Street's $295.6M, and wrote down in advance what each branch is worth: +$0.83, $0 or −$1.38 a share.
• There is no squeeze setup. Short interest is 26.6% of the freely traded shares, down from about 34% before the May 2025 results. Borrowing the stock costs about 0.3% a year, and shares available to borrow doubled from 3M to 6M. The swarm treats short interest as something that can enlarge a move, not as a reason to expect one.

Regulatory risk is real but sits mostly outside the guidance

Charges from the FTC, SEC and DOJ matters are added back to adjusted EBITDA, so they do not touch the $275–325M guidance. The real risks are a large settlement, a court order against Hims' billing practices, or an SEC escalation. The swarm carries about $30M a year of probability-weighted EBITDA at risk, and models a separate severe regulatory scenario with a 4.8% chance.

• The FTC case. On 22 October, Hims moved to dismiss the case (hearing on 7 January), and its request to postpone the 30 October case conference was denied. The swarm puts a 92% chance on no settlement and no injunction motion before the results.
• The peptide rule. An FDA policy on compounding certain peptides went to the White House budget office on 14 October. A report about it on 15 October lifted the stock 6%. The swarm puts a 30% chance on publication before the results, and treats it as a headline event, not a change in value.

A stock can be overvalued and still not be a good short

The case for a short looks easy: fair value of $22.86 against a $27.71 stock, a falling margin, and a stock that has fallen after 7 of its last 8 results. The swarm declined, for four reasons:

1. The downside is already priced. Options give a 36% chance of a 10%-plus fall; the swarm says 35%.
2. The upside tail is large. In the bull case, retention holds, margin recovers toward 64–65% and the 2030 target is roughly met. That case is worth $46.52 a share, with a 27.6% chance. Reward against risk is 0.82x, short of what the swarm requires to act.
3. The edge rests on one forecast. The view is a call on margin and cash, and the swarm labels part of it as an accounting convention the market may never use.
4. Its first trading rule could never trigger. The original rule was to act only if the price fell outside the range of scenario values. That range, $6.35–$46.52, is so wide the rule could never fire. The swarm replaced it with an explicit decision, re-argued in writing every 24 hours, with named conditions that would change it:
   • a put spread (an options bet on a fall, with the loss capped) if the stock reaches $32 with no evidence on margin, or after a fresh regulatory setback, sized at no more than 0.25% of the portfolio;
   • a call spread (the same bet on a rise) at $20 or below.

In October, the stock traded between $26.33 and $31.79, so neither level was hit. The swarm's stance is no trade, with entry levels set, and the decision waits for the facts on 9 November.

Every outcome of the 9 November results is scored in advance

The swarm's six outcomes for 9 November imply a 6.9% fall on average Hims & Hers: chance of each results outcome (%), with the stock move the swarm expects for it.

The probability-weighted move is −6.9%, with a 73% chance the stock falls. The options market expects a 12.5% move in either direction.

Of its 57 dated predictions, 53 are graded within a day of the results. The odds give weight to the company's record of beating guidance as well as to the swarm's own cost model, so they are kinder to Hims than its $74.5M point forecast:

Three tests land before the results:

Each prediction records what the swarm will change if it is wrong: which input, and by how many dollars a share.

Why fair value has held since 27 September

Fair value has not moved since 27 September. That is not for lack of work: almost everything that would settle the open questions (Q3 margin, the Q4 guidance, cash flow without the receivables facility, weight-loss retention) is answered only by the 9 November results. Two small findings, a +$0.10 tilt from the pricing tree and the roughly −$0.35 compounded run-off, sit as tests for the results rather than changes to the number. While it waits, the swarm runs once a day.

Each question is built to settle an open debate

The swarm drafted 28 questions for management and 42 for six kinds of expert: prescribing clinicians, compounding pharmacists, competitor operators, former employees, drug-pricing specialists and regulatory lawyers. Each records, before anyone asks, what the swarm believes now, what the answer is worth per share, and what answer would change its view.

Every management question starts from something the company has said:

Hims & Hers, for management (About $1.40 to $2.80 a share)

"On the Q2 call you said you expect the gross margin dynamics of the second quarter to persist through the second half. Should we read 'persist' as the Q2 level of about 64% being the right reference for the back half, or as the same mix forces continuing, which on our math takes the blended margin lower once Eucalyptus is in for a full quarter?"

The swarm's single biggest debate, reduced to one word in one sentence from the CFO. If management names 64% as the reference, the swarm moves its Q3 margin toward 62–63%.

Hims & Hers, for management

"You hold new investments to a payback of a year or less. Do branded weight-loss customers, acquired at today's prices and on monthly billing, meet that standard on their own gross profit, and if they did not, what would you change first: price, marketing intensity, or the weight of weight loss in the funnel?"

This holds management to its own investment rule. On the swarm's numbers, a branded weight-loss customer returns about 0.7x its acquisition cost over 24 months.

Hims & Hers, for management (±10% on acquisition cost moves about $13 a share)

"Search interest in the Hims brand is down about a fifth year on year on our measurement, yet you describe years of brand investment lifting acquisition in lower-cost channels. How do you reconcile the two?"

This goes after customer acquisition cost, the biggest lever on value.

The expert questions go where management cannot:

Hims & Hers, for a drug-pricing specialist

"When a manufacturer supplies a telehealth partner that sells its GLP-1 at the manufacturer's own self-pay price, how is the partner's net drug cost typically set: equal to the self-pay price, or below it through a discount, rebate or distribution fee, and in what range as a share of the self-pay price?"

Hims & Hers, for a former employee

"Hims says cohort payback has run about 6 to 7 months for four years. In your experience, how was that metric built, and what range of acquisition cost per new paying subscriber would you consider typical for legacy categories such as sexual health and hair loss in 2024-2025?"

Hims & Hers, for a regulatory lawyer

"If FTC v. Hims ends in a settlement or order, what conduct terms are most likely, and would a ban on using health information for advertising, as in the GoodRx, BetterHelp, Cerebral and Monument orders, reach conversion signals, custom audiences and lookalikes built from intake or purchase data?"

What this means for investment teams

Hims is one of the three swarms in Introducing Matterfact Agent Swarms. An Agent Swarm on Borr Drilling shows the same method on a levered, cyclical company. Four lessons stand out.

In a business in transition, the adjusted numbers are the weakest link. Cash EBITDA, a deferred-revenue release, rebate receivables and a receivables-sale facility each say more about Hims' second half than headline EBITDA does. Every one came from a filing note, not a press release.

Being right only pays when the market is wrong. The swarm's bear case was right on the facts and wrong as a trade, because the options market already expected it.

Know which lever moves the value. The debate everyone has, weight-loss margin, is the smallest lever. Acquisition cost and churn in the core business are about four times bigger.

Correct in both directions. The swarm threw out a bearish argument on its first day, added $1.77 back when the company's record required it, and labelled most of its biggest cut as method rather than business.

On 9 November, Hims reports, and 53 of the swarm's predictions are graded within a day.

Read the swarm's investment memo

The swarm's investment committee memo sets out the full case in the format a portfolio manager would expect: the stance and trade plan, the variant view against the Street, valuation, catalysts, risks, and appendices on unit economics, margins and cash quality, weight-loss competition and regulation, the capital structure, and the results-day setup.

It is the swarm's 25 September version, so it uses that day's $29.42 share price and the 2 November results date that Hims later moved to 9 November. The fair value of $22.86 is unchanged since then.

kind: word
title: Hims & Hers investment memo
meta: Written by the agent swarm · as of 25 Sep 2026 · Word, 612 KB
href: /samples/hims-hers-ic-memo-2026-09-25.docx

This post and the investment memo describe research outputs from a Matterfact agent swarm, shown to illustrate how the system works. They are not investment advice or a recommendation to buy or sell any security. Any trades or stances described are hypothetical model outputs, not actual trades.